Good afternoon :)
$
₹
Smith & Nephew SNATS Inc

Smith & Nephew SNATS Inc

SNN

NYSE
Asset Logo

Smith & Nephew SNATS Inc

SNN

NYSE
$30.830.13% (-0.04)
$
₹
$30.830.13% (-0.04)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Large Cap

With a market cap of $12.2B the stock is ranked 854

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

19.88
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.22
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$1.47
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.05
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

10.08%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

2.72%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 6 analysts reports

Buy
1 analyst
Hold
5 analysts
Sell
0 analyst

Price Upside

+4.84%

Earnings Growth

+213.23%

Rev. Growth

+4.89%

See Detailed Forecast

Company Profile

Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
37.36
37.36
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.71
38.71
1Y Return
3.48%
3.48%
Buy Reco %
88.00
88.00
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
51.76
51.76
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
22.85
22.85
1Y Return
1.27%
1.27%
Buy Reco %
65.51
65.51
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
30.83
30.83
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 4.84% growth, versus a trailing 3-year CAGR of 13.40%.

2026
Current$30.83Baseline
Analyst Target - 1 year
Target$32.32+4.84%

All values in $

202220232024202520262027$25.21$28.84$32.46Target+4.84%
2026
Current$30.83Baseline
Analyst Target - 1 year
Target$32.32+4.84%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 4.89% growth, versus a trailing 3-year CAGR of 5.73%.

2025
Current$6.16Baseline
Forecast for Dec 2026
High$6.6+7.07%
Average$6.46+4.89%
Low$6.39+3.8%

All values in $ Billion

2021202220232024202520265.215.215.545.816.16Low+3.8%Average+4.89%High+7.07%
2025
Current$6.16Baseline
Forecast for Dec 2026
High$6.6+7.07%
Average$6.46+4.89%
Low$6.39+3.8%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 213.23% growth, versus a trailing 3-year CAGR of 41.61%.

2025
Current$0.71Baseline
Forecast for Dec 2026
High$2.27+219.72%
Average$2.22+213.23%
Low$2.19+208.45%

All values in $

2021202220232024202520261.260.251.660.990.71Low+208.45%Average+213.23%High+219.72%
2025
Current$0.71Baseline
Forecast for Dec 2026
High$2.27+219.72%
Average$2.22+213.23%
Low$2.19+208.45%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

2.9
0.1
2.9
0.2
3.2
0.3
3
0.3
Q4 2024
Q2 2025
Q4 2025
Q2 2026
Revenue
Net Income
Financial YearQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q4 2024Q2 2025Q4 2025Q2 2026
Total Revenue1.362.731.402.811.412.822.982.963.203.09
Net Income0.080.170.040.090.100.210.190.290.330.30
Net Profit Margin6.29%6.29%3.23%3.23%7.56%7.56%6.63%9.89%10.36%9.78%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Smith & Nephew SNATS Inc 19.882.221.05
Abbott Laboratories37.363.501.89
Danaher Corporation38.712.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare SNN with any stock or ETF
Compare SNN with any stock or ETF
Comparing from
SNN
ABT
DHR
Loading...

Frequently asked questions

  1. Smith & Nephew SNATS Inc (SNN) share price today is $30.83 as of October 24, 2026 at 1:29 AM IST. The stock touched a day high of $31.16 and a day low of $30.83.

  2. Smith & Nephew SNATS Inc stock trades on NYSE under the ticker symbol SNN.

  3. Smith & Nephew SNATS Inc's market capitalization is $12.23B as of October 24, 2026 at 1:29 AM IST.

  4. Smith & Nephew SNATS Inc's price-to-earnings (P/E) ratio is 19.88 as of October 23, 2026.

  5. Smith & Nephew SNATS Inc's price-to-book (P/B) ratio is 2.22 as of October 23, 2026.

  6. Yes, Smith & Nephew SNATS Inc pays a dividend, with a current dividend yield of 2.72%.

  7. Yes, You can buy Smith & Nephew SNATS Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Smith & Nephew SNATS Inc shares in three steps: 1. Search Smith & Nephew SNATS Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Smith & Nephew SNATS Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Smith & Nephew SNATS Inc (SNN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.3242 shares at the current price of $30.83.

Loading...